Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms

被引：8

作者：

Kuchnio, Anna ^{[1
]}

Samakai, Elsie ^{[2
]}

Hug, Eva ^{[3
]}

Balmana, Meritxell ^{[3
]}

Janssen, Lut ^{[1
]}

Amorim, Ricardo ^{[1
]}

Cornelissen, Ivo ^{[1
]}

Majoros, Andrea ^{[3
]}

Broux, Michael ^{[1
]}

Taneja, Isha ^{[2
]}

Torti, Vince ^{[4
]}

Agic, Azra ^{[3
]}

Moritsch, Stefan ^{[3
]}

Benedetti, Filippo ^{[3
]}

Rosebrock, Felix ^{[3
]}

Packman, Kathryn ^{[5
]}

Arts, Janine ^{[6
]}

Patel, Sonal ^{[7
]}

Lomas, Oliver Christopher ^{[8
]}

Deyoung, M. Phillip ^{[2
]}

Zagrijtschuk, Oleh ^{[3
]}

Elsayed, Yusri ^{[9
]}

Constantinescu, Stefan ^{[10
,11
,12
,13
]}

Kralovics, Robert ^{[14
]}

Philippar, Ulrike ^{[15
]}

机构：

[1] Janssen Res & Dev, Beerse, Belgium

[2] Janssen Res & Dev, Spring House, PA USA

[3] MyeloPro Diagnost & Res GmbH, Vienna, Austria

[4] Janssen Res & Dev, La Jolla, CA USA

[5] Janssen Res & Dev LLC, Cambridge, MA USA

[6] Janssen Sci Innovat Oncol, Beerse, Belgium

[7] Janssen Sci Innovat Oncol, London, England

[8] Janssen Res & Dev, High Wycombe, England

[9] Janssen Res & Dev LLC, Spring House, PA USA

[10] Ludwig Inst Canc Res, Brussels, Belgium

[11] UCLouvain, Duve Inst, Brussels, Belgium

[12] Wel Res Inst, Welbio Dept, Wavre, Belgium

[13] Univ Oxford, Nuffield Dept Med, Ludwig Canc Res Oxford, Oxford, England

[14] Med Univ Vienna, Vienna, Austria

[15] Janssen Res & Dev LLC, Beerse, Belgium

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173430

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 44 条

[41] Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors.
Melero, Ignacio
Segal, Neil Howard
Suarez, Jose M. Saro
Ros, Willeke
Garcia, Maria Martinez
Calvo, Emiliano
Moreno, Victor
Aix, Santiago Ponce
Marabelle, Aurelien
Cleary, James M.
Hurwitz, Herbert
Eder, Joseph Paul
Jamois, Cancize
Belousov, Anton
Bouseida, Said
Sandoval, Federico
Bacac, Marina
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42] First-line chemoimmunotherapy in metastatic breast carcinoma: Effect of a combination of paclitaxel and LAG-3-ig (IMP321), a novel MHC class II agonist, on T-cell responses and antitumor activity
Gutierrez, M.
Brignone, C.
Mefti, F.
Triebel, F.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[43] Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment
Sullivan, Ryan J.
Liu, Ke
Redman, Jason M.
Tschernia, Nicholas
Bayliffe, Andrew
Marino, Alyssa
Srinivasan, Karunya
Katragadda, Madan
Moisan, Jacques
Chopra, Rajesh
Marabelle, Aurelien
Kaufman, Howard L.
Siu, Lillian L.
Su, Zhen
Gulley, James L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44] INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Hansen, Aaron Richard
Stanton, Thomas S.
Hong, Min Hee
Cohen, Ezra E. W.
Mehanna, Hisham Mohamed
Chisamore, Michael Jon
Turner, David
Yadavilli, Sapna
Bell, Kelly
Baccan, Carlos
Leone, Rosalida
Chen, Helen
Zhou, Helen
Ellis, Catherine Elizabeth
Ballas, Marc S.
Hoos, Axel
Rischin, Danny
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →